There are approximately 50 million arthritis patients in the U.S., and the Arthritis Foundation made history on Tuesday as the first patient advocacy group to provide CBD guidance.
While the group didn’t directly recommend that patients can use CBD to treat arthritis, they nevertheless observed that lots of patients have exhibited interest in, or actually used CBD in their quest for pain relief. This observation mirrors what we reported about a medical expert who wasn’t opposed to patients using CBD to manage their pain.
The group expressed its interest in CBD and urged the FDA to expedite research into CBD products in addition to regulating the industry.
The Foundation also revealed to its members that to date, no serious safety issues have been recorded among people who use moderate amounts of CBD. However, the Foundation was also quick to note that CBD may interact with the other medicines that patients are taking to manage their arthritis symptoms.
The Arthritis Foundation also included many specific recommendations that patients would be well advised to keep in mind when considering CBD products.
For example, the foundation strongly advised patients to opt for CBD products that were manufactured within the U.S. using crops grown in the country. This precaution is important because local growers and processors follow state or federal regulations, so patients are likely to face fewer risks associated with product quality.
The group also warned patients against using CBD products that are intended to be vaporized, especially patients with inflammatory types of arthritis. This precaution may even take on greater importance given the recent wave of pulmonary illnesses linked to tainted cannabis vape cartridges.
Patients are also advised to talk to a health care professional before they start using CBD products for arthritis. People who sell CBD products are usually salesmen and women, and the advice that they give on how to use the CBD product may not necessarily be accurate.
The Arthritis Foundation also recommends that patients refrain from buying CBD products that contain THC since the THC could impair their cognitive, psychomotor and other abilities. The patients were also advised to consider the laws of their area regarding which CBD products are permitted and which ones aren’t. Only buy the products that are legal in your area since these may have been made in accordance with the existing industry regulations, if any.
This is sound advice that analysts believe doesn’t depart from what industry players like SinglePoint Inc. (OTCQB: SING) and Sugarmade Inc. (OTCQB: SGMD) have been giving all users of CBD products.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
